Anas Younes, SVP, CMO and Global Head of Hematology, Oncology R&D at AstraZeneca, shared a post on LinkedIn:
“I’m proud of what our AstraZeneca teams achieved in 2025.
Fresh in my mind is ASH25 – an annual pulse check of how much our field has advanced in 12 months. Our AstraZeneca teams presented key clinical data including on a next-generation T-cell engager molecule and our first cell therapy clinical trial. Our hematology pipeline is maturing, with 6 early clinical starts in 2025. Thank you to the teams leading these clinical programs and to our discovery colleagues who enabled this diverse pipeline!
Nothing energizes me more than time with our teams and collaborators around the world. 2025 highlights include visiting teams in the Netherlands and Cambridge, and meeting with leading cancer centers in China. I’m grateful for perspectives on how to accelerate delivery of our pipeline. The future of hematology would be shaped by how boldly we challenge the status quo and how far ahead we look.
This year, I was thrilled to appoint Rakesh Kumar as VP, Hematology Projects and Nicholas Durham to lead Hematology Translational Medicine. In August, I was honored to be appointed Chief Medical Officer for AstraZeneca – a role that enables me to deepen the patient focus that has anchored my career as a clinician-scientist. As CMO and Head of Haematology R&D, I’m committed to working with purpose and urgency with the aim to bring our medicines to patients around the world to potentially improve health outcomes and equity.
Time to mark our calendars for the 2026 congresses! Take care this holiday season.”
Proceed to the video attached to the post.
More posts featuring Anas Younes.